Trial Profile
Xenera-1: A multi-centre, double-blind, placebo-controlled, randomised phase II trial to compare efficacy of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in women with HR+ / HER2- metastatic breast cancer and non-visceral disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs Xentuzumab (Primary) ; Everolimus; Exemestane
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms XENERA-1
- Sponsors Boehringer Ingelheim
- 01 Feb 2024 This trial has been Discontinued in Portugal, According to European Clinical Trials Database record.
- 23 Sep 2023 This trial has been discontinued in Spain, according to European Clinical Trials Database record.
- 11 May 2022 Status changed from active, no longer recruiting to completed.